Magenta Therapeutics

Magenta Therapeutics was co-founded, seeded, and incubated by Atlas in 2015 to revolutionize stem cell transplant as the new treatment paradigm for autoimmune and blood-based diseases. By more effectively preparing patients to receive stem cell transplants and delivering higher quality replacement stem cells, Magenta aims to make curative stem cell therapies available to substantially more patients than are currently receiving these life-saving treatments. Magenta went public in June 2018 (NASDAQ: MGTA). Magenta bags $52M Series C for bone marrow transplant pipeline Cambridge star Magenta teams up with Heidelberg on bone marrow R&D pact that includes $334M in potential milestones Magenta Therapeutics named a 2017 Fierce15 winner by FierceBiotech Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it Stem Cell Transplant Startup With Harvard Tech, Magenta Therapeutics, Gets $48.5M GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round From the Trenches: Rebooting The Conversation Two venture firms launch Cambridge biotech with $48.5m in funding